Home / Tech News / Medical care scheduling startup Doctolib acquires MonDocteur

Medical care scheduling startup Doctolib acquires MonDocteur

What do you do when you’ve raised nearly $100 million and you want to grow as quickly as possible? In Doctolib’s case, the startup is acquiring its main competitor MonDocteur . Together, the two companies work with tens of thousands of doctors and get tens of millions of unique visitors every month. Doctolib has developed an online scheduling platform for all sorts of doctors, from your physician next door to the hospital in the big city. Instead of creating integrations with existing calendars and software solutions, Doctolib is replacing your doctor’s scheduling system altogether. After signing up, you can create your profile and manage your calendar from Doctolib directly. This way, patients can look at their doctor’s calendar on Doctolib’s website and find a time slot that works for everyone. But doctors even use Doctolib for patients who call them directly as it replaces the entire calendar system. MonDocteur started five years ago with the exact same idea in mind. Over time, the two companies have significantly grown and convinced more and more doctors. You can’t use both solutions, so each doctor had to decide between Doctolib and MonDocteur. Here are some numbers: MonDocteur has 150 employees, while Doctolib has 450 employees.

More:
Medical care scheduling startup Doctolib acquires MonDocteur

About Tech News Reporter

Check Also

Inside the rise and reign of supergiant venture capital rounds

There was a time not so long ago when nine-figure venture capital rounds weren’t a near-daily feature of tech business news. But now funding rounds of $100 million or more cross the wires with  stunning frequency . The  era of supergiant rounds  is now the new normal. This is attributable, in part, to billions of dollars flowing into new venture capital funds — the largest of which are raised by the oldest, most entrenched firms — and competition from relative newcomers, like  SoftBank . Q2 2018 may have set new records for worldwide VC deal and dollar volume in this post-dot com cycle, but that belies an important fact: Investors are dumping the bulk of capital into a relatively small number of companies. The rise of supergiant rounds wound up in a “takeover” of the market. The chart below shows the proportion of capital raised in rounds of $100 million or more, tracing the period between Q1 2017 and the end of Q2 2018. Just a little over a year ago, in Q1 2017, nine and 10-figure venture capital deals accounted for a healthy 35 percent of global dollar volume. Five quarters later, in Q2 2018, $100 million-and-up deals accounted for a majority — some 61 percent — of equity funding into upstart technology companies. It’s not just that these mega-rounds are eclipsing smaller counterparts as a percent of dollar volume totals. Supergiant rounds also appear to be driving most of the growth in reported dollar volume, as the chart below shows. Between Q1 2017 and Q2 2018, reported dollar volume in sub-$100 million deals grew by around 42 percent. By that same token, dollar volume in nine and 10-figure venture deals ballooned by about 325 percent over that stretch of time. Granted, this is all based on recorded data in Crunchbase. And like all private-market databases, Crunchbase is subject to some reporting delays

Leave a Reply

Your email address will not be published. Required fields are marked *